Home Neoplasma 2018 Neoplasma Vol.65, No.5, p.720-729, 2018

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.5, p.720-729, 2018

Title: Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy
Author: S.K. CHANG, J. HOU, G.G. CHEN, D.D. YU, H.Q. WU, Y.S. XIE, L.N. HU, L. GAO, W.Q. XIAO, Y.Y. KONG, J.M. SHI

Abstract: Natural killer (NK) cell-based immunotherapy is promising, because NK cells form the first line of defense against cancer and are capable of lysing tumor cells without pre-stimulation. However, NK cells from multiple myeloma (MM) patients are always deficient in number, and the expression of certain activating receptors disables their cancer cyto-toxicity. Therefore, effective strategies to expand NK cells and increase NK cell-mediated cyto-toxicity against MM are imperative. Herein, NK cells were efficiently expanded from peripheral blood mononuclear cells (PBMCs) of newly diagnosed MM patients after co-culture with irradiated K562 cells transfected with 41BBL and membrane-bound interleukin (IL)-15 (K562-mb15-41BBL) in the presence of 200 IU/ml human IL-2. The ex vivo-expanded NK cells were demonstrated to vigorously kill both MM cells and autologous primary MM cells without significant lysis of normal patient cells. Further exploration revealed significant increase in cell surface expression of most activating receptors of NK cells and indicated that expanded NK (exp-NK) cell killing of MM cells was mediated by perforin/granzyme. NK cells are capable of lysing human leukocyte antigen (HLA) I-deficient tumor cells and carfizomib, a selective proteasome inhibitor approved for the treatment of relapsed/refractory MM patients down-regulates the expression of HLA class I, thus enhancing NK cell-mediated lysis in MM. Herein, we established for the first time that carfizomib dramatically augmented ex vivo exp-NK cell cytotoxicity against patient autologous MM cells, thus suggesting successful use of exp-NK alone or in combination with the drug in treating MM patient.

Keywords: carfilzomib, natural killer cell, ex vivo expansion, multiple myeloma, immunotherapy, K562-mb15-41BBL
Published online: 24-Sep-2018
Year: 2018, Volume: 65, Issue: 5 Page From: 720, Page To: 729

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.